Journal of Clinical Oncology, Vol 12, 1592-1599, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Tumor response, toxicity, and survival after neoadjuvant organ- preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group

MB Spaulding, SG Fischer and GT Wolf
Department of Medicine, State University of New York at Buffalo.

PURPOSE: In 1984, the Department of Veterans Affairs Cooperative Studies Program began a trial in which patients with resectable squamous cell carcinoma of the larynx were randomized to receive standard surgery followed by radiation therapy or to receive neoadjuvant therapy with cisplatin and fluorouracil (5-FU) followed by radiation therapy for those achieving a greater than 50% tumor response to chemotherapy. This analysis reviews the tumor responses, toxicity, compliance, and long-term survival for those patients randomized to the chemotherapy arm. PATIENTS AND METHODS: One hundred sixty-six patients were randomized to the chemotherapy arm. Standard tumor response data, chemotherapy toxicity, and survival have been examined using standard statistical methods. RESULTS: The high response rates and acceptable toxicity to cisplatin and 5-FU of previously untreated patients were confirmed. Long-term disease-free survival was more likely to occur in patients who achieved a complete response to chemotherapy, particularly in those who had a confirmed histologic response to chemotherapy. Pretreatment histologic growth patterns were highly predictive of responses to chemotherapy. CONCLUSION: Neoadjuvant chemotherapy was well tolerated and did not negatively affect the definitive treatment that followed. The survival of nonresponding patients who underwent prompt salvage surgery was also not impaired. The role of organ preservation should be explored in other head and neck sites.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Glynne-Jones and P. Hoskin Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm? J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286. [Abstract] [Full Text] [PDF]

				D. G. Pfister, S. A. Laurie, G. S. Weinstein, W. M. Mendenhall, D. J. Adelstein, K. K. Ang, G. L. Clayman, S. G. Fisher, A. A. Forastiere, L. B. Harrison, et al. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer J. Clin. Oncol., August 1, 2006; 24(22): 3693 - 3704. [Abstract] [Full Text] [PDF]

				R. Haddad, R. Tishler, L. Wirth, C. M. Norris, L. Goguen, C. Sullivan, L. O'Donnell, Y. Li, and M. Posner Rate of pathologic complete responses to docetaxel, Cisplatin, and Fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 678 - 681. [Abstract] [Full Text] [PDF]

				S. Urba, G. Wolf, A. Eisbruch, F. Worden, J. Lee, C. Bradford, T. Teknos, D. Chepeha, M. Prince, N. Hogikyan, et al. Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm J. Clin. Oncol., February 1, 2006; 24(4): 593 - 598. [Abstract] [Full Text] [PDF]

				D. G. Pfister and J. A. Ridge Induction Chemotherapy for Larynx Preservation: Patient Selection or Therapeutic Effect? J. Clin. Oncol., February 1, 2006; 24(4): 540 - 543. [Full Text] [PDF]

				B. T. Hennessy, G. N. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. U. Buzdar, S. W. Kau, B. Fornage, A. Sahin, K. Broglio, et al. Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy J. Clin. Oncol., December 20, 2005; 23(36): 9304 - 9311. [Abstract] [Full Text] [PDF]

				R. Haddad, R. B. Tishler, C. M. Norris, A. Mahadevan, P. Busse, L. Wirth, L. A. Goguen, C. A. Sullivan, R. Costello, M. A. Case, et al. Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment Oncologist, February 1, 2003; 8(1): 35 - 44. [Abstract] [Full Text] [PDF]

				C. Monnerat, S. Faivre, S. Temam, J. Bourhis, and E. Raymond End points for new agents in induction chemotherapy for locally advanced head and neck cancers Ann. Onc., July 1, 2002; 13(7): 995 - 1006. [Abstract] [Full Text] [PDF]

				M. R. Posner, B. Glisson, G. Frenette, M. Al-Sarraf, A. D. Colevas, C. M. Norris, J. D. Seroskie, D. M. Shin, R. Olivares, and C. A. Garay Multicenter Phase I-II Trial of Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy for Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck J. Clin. Oncol., February 15, 2001; 19(4): 1096 - 1104. [Abstract] [Full Text] [PDF]

				A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473. [Abstract] [Full Text] [PDF]

				V. J. Lowe, J. H. Boyd, F. R. Dunphy, H. Kim, T. Dunleavy, B. T. Collins, D. Martin, B. C. Stack Jr, C. Hollenbeak, and J. W. Fletcher Surveillance for Recurrent Head and Neck Cancer Using Positron Emission Tomography J. Clin. Oncol., February 1, 2000; 18(3): 651 - 651. [Abstract] [Full Text] [PDF]

				S. Temam, A. Flahault, S. Perie, G. Monceaux, F. Coulet, P. Callard, J.-F. Bernaudin, J. L. St Guily, and P. Fouret p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., January 14, 2000; 18(2): 385 - 385. [Abstract] [Full Text] [PDF]